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StabilityIntegration of exogenous DNA into modiﬁed vaccinia Ankara (MVA) is often accomplished using mapped
deletion sites in the viral genome. Since MVA has a large capacity (≥30 kb) for foreign gene inserts and a
limited number of unique integration sites, development of additional integration sites is needed to take full
advantage of the extraordinary capacity for foreign gene insertion. In this report, we evaluate an alternative
insertion site known as intergenic region 3 (IGR3). Recombinant MVA carrying the cytomegalovirus pp65
gene in IGR3 (rMVA-pp65-IGR3) demonstrated expression and genetic stability of the insert gene upon
passage. Immunization of transgenic HLA-A2 mice with rMVA-pp65-IGR3 induced robust antigen-speciﬁc
immune responses. Moreover, rMVA-pp65-IGR3-infected human EBV-transformed B cell lines were able to
stimulate high levels of pp65-speciﬁc memory T cell responses in human PBMCs. These data support the
usage of IGR3 for the development of highly immunogenic rMVA vaccines for clinical or veterinary use.ccine Research Fox South, Rm.
500 East Duarte Rd. Duarte CA.
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Enhancing the stability and immunogenic properties of transgenes
inserted into MVA is vital for the generation of effective vaccines for
use against infectious disease and cancer (Amato et al., 2009; Earl et
al., 2007, 2009; Gomez et al., 2008; Hodge et al., 2003; Meyer et al.,
2005). MVA itself is avirulent, even in immunocompromised
individuals, yet it has the ability to induce signiﬁcant immune
responses to targeted transgene products (Gherardi and Esteban,
2005; Mayr and Danner, 1978; Moss, 1996; Ramirez et al., 2000;
Wang et al., 2004a, 2008). Deletion (del) sites represent non-essential
regions in the MVA genome whose deletion minimally impacts MVA
viability in chicken embryo ﬁbroblasts (CEFs). These regions formed
during the process of 570 serial passages on CEFs that transformed the
pathogenic vaccinia virus Ankara strain intoMVA (Meyer et al., 1991).
Del sites have been routinely used for insertion of recombinant genes
encoding tumor- and virus-associated antigens to formMVA vaccines
(Drexler et al., 2004). However, the stability of certain transgenes in
del sites is variable depending on the toxicity of the expressed product
during cellular and viral replication (Wyatt et al., 2008). In some
cases, mutations or deletions that occur in transgenes after several
passages of rMVA in culture may result in reduced or complete loss ofexpression (Wyatt et al., 2009). Therefore, alternative insertion sites
known as intergenic regions (IGRs) within the MVA genome have
been identiﬁed and studied for their support of stable transgene
expression. A recent report described the stable insertion of HIV
subunit genes into a site located between the essential I8R and GIL
genes in the central conserved region of MVA (Wyatt et al., 2009).
Recent studies have also looked at the genetic stability of transgenes
in IGRs (Timm et al., 2006), but have not yet assessed their
immunogenic properties. To this end, we have evaluated the stability
and immunogenicity of a model cytomegalovirus (CMV) antigen
(pp65) inserted speciﬁcally into intergenic region 3 (IGR3) (Howley
and Leyrer, 2009) (Timm et al., 2006).
Results
Construction of rMVA-pp65-IGR3
To investigate the properties of IGR3, a transfer vector was ﬁrst
generated to target the IGR3 site located between the essential I3L
(Rochester and Traktman, 1998) and nonessential I4L genes (Howley
et al., 1996b) spanning nucleotide positions 56,152 to 57,343 of the
MVA genome for insertion of an expression cassette carrying the
CMV-pp65 gene (McLaughlin-Taylor et al., 1994; Wang et al., 2007).
As shown in Fig. 1A, the IGR3 sequence of the MVA genome was ﬁrst
ampliﬁed by PCR using primers containing EcoRI restriction sites
ﬂanking the IGR3 site for insertion into the pCR2.1 vector (Invitro-
gen). SalI/Acc65I restriction enzyme sites were inserted into the IGR3
site in preparation to accept an expression cassette containing a
Fig. 1. Construction of recombinant MVA-pp65-IGR3. (A) Schematic for mH5-pZWIGR3 transfer vector construction. Shown is a representation of the region of the MVA genome
where IGR3 is located between the I3L (ORF 064) and I4L (ORF 065) genes. Two sets of primers were used to amplify individual regions of the IGR3 that would be used in the ﬁnal
transfer vector shown in C. The left most portion is approximately 596 base pairs and corresponds to IGR3-FL1, while the right fragment is approximately 607 base pairs and
represents IGR3-FL2. Sequences of the primers and methods for ampliﬁcation are described in Table 1 and Materials and Methods. The IGR3 region of the MVA genome was ﬁrst
ampliﬁed using primers containing EcoRI sites for cloning into pCR2.1 (pCR2.1-IGR3). (B) An expression cassette containing a multiple cloning site (MCS), modiﬁed H5 promoter
(mH5) and ﬂuorescent selectionmarker cassette (Venus™, Clontech) was inserted into pCR2.1-IGR3 using SalI and Acc65I restriction sites. The Sal1-Acc65I fragment bisects the IGR3
ampliﬁed region into two segments that are referred to as IGR3-FL1 and IGR3-FL2. (C) The expression cassette ﬂanked by IGR3 (FL1 and FL2) was then inserted into themH5-pZWIIA
transfer vector (Wang et al., 2010) using EcoRI restriction sites (mH5-pZWIGR3). The mH5-pZWIGR3 transfer vector was used to generate recombinant MVA (rMVA-pp65-IGR3) by
homologous recombination. Procedures and primer sequences are described in Table 1 and Materials and Methods.
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2010), a multiple cloning site (MCS), a p7.5 promoter (Chakrabarti et
al., 1985) and the Venus™ (Clontech) ﬂuorescent marker gene (Nagai
et al., 2002) used for screening of recombinant viral plaques (Fig. 1B).
In the ﬁnal assembled transfer vector, mH5-pZWIGR3, the expression
cassette is placed within the IGR3 site splitting it into two ﬂanking
segments (Fig. 1C). For this study, the CMV-pp65 gene was inserted
into the MCS of the transfer vector and then used to generate rMVA
carrying the CMV-pp65 transgene in IGR3 (rMVA-pp65-IGR3) by
homologous recombination in BHK-21 cells using established proto-
cols (Moss and Earl, 1998; Wang et al., 2007; Yue et al., 2008).
Comparison of viral properties of Del II and IGR3 insertion site viruses
Although the Venus™ ﬂuorescent marker gene allows for rapid
screening of recombinant virus, it does not guarantee the presence of
transgene products since it is not fused to the insert gene. Therefore,
preliminary analysis of expression levels of CMV-pp65 was performed
following 5 rounds of screening based on immunostaining of BHK-21
cells infected with isolates of rMVA-pp65-IGR3 or isolates containing
CMV-pp65 in the del II insertion site (rMVA-pp65-del II) (Fig. 2A). The
size and degree of spread of rMVA-infected, pp65-positive BHK-21
cells, indicated by darker staining cells, was comparable between
rMVA carrying pp65 in either IGR3 or del II insertion sites. These data
suggest that insertion of CMV-pp65 is equally well tolerated in both
del II and IGR3 sites.
Insertion of exogenous DNA into the MVA genome can potentially
reduce the ﬁtness of the recombinant virus and prevent optimal
replication, making it difﬁcult to obtain titers of virus sufﬁcient for
vaccine development. Thus, subsequent to puriﬁcation, the viral
growth kinetics of rMVA-pp65-IGR3 was evaluated in both BHK-21
and CEF cells, following infection with a starting concentration of
4.0×104 pfu/ml (multiplicity of infection (MOI)=0.01), by deter-mining viral titers at various time points through immunostaining
against rMVA (Fig. 2B). Viral replication reached maximal titers
ranging from 108-109 pfu/ml in both BHK-21 and CEF cells, which is
not signiﬁcantly different from titers observed with wildtype or
rMVAs carrying other transgenes in del II or del III sites (Drexler et al.,
1998). These data strongly suggest that recombination of the CMV-
pp65 expression cassette into IGR3 does not interrupt expression
from the essential I3L gene, since doing so would have resulted in
minimal production of recombinant virus(Howley et al., 1996a).
Conﬁrming unimpeded replication kinetics, we then proceeded to
purify rMVA-pp65-IGR3 following 8 rounds of screening and
performed western blot (WB) analysis for CMV-pp65 expression in
lysates of BHK-21 cells infected with the puriﬁed virus. Using equal
amounts of total protein lysate (Bradford assay), we observed CMV-
pp65 expression from rMVA-pp65-IGR3-infected BHK-21 cells that
was comparable to that of rMVA-pp65-del II-infected BHK-21 cells
(Fig. 2C). These data further validate the equivalence of insert
expression in both viruses and the functional expression properties
of rMVA carrying transgenes in the IGR3 site.
Genetic stability of rMVA-pp65-IGR3 upon serial passage
The genetic stability of a live rMVA vaccine is critical for
maintaining potency and feasibility of manufacture. Verifying the
expression of the transgene product over numerous passages, though
important, will not necessarily indicate which fraction of the viral
population has lost the inserted transgene. Therefore, we sought to
determine the percentage of rMVA maintaining the CMV-pp65
transgene following multiple passages in vitro. We ﬁrst measured
the genetic stability of CMV-pp65 in IGR3 by performing real-time
PCR analysis (ABI 7300 Real-Time PCR System) to detect the ratio of
the CMV-pp65 transgene toMVA backbone over 10 passages of rMVA-
pp65-IGR3 in BHK-21 cells. As shown in Fig. 3A, the transgene to MVA
Fig. 2. Viability and expression levels of rMVA-pp65-IGR3. (A) Expression of transgene
product (CMV-pp65) during screening process of rMVA-pp65-IGR3. Following 5 rounds
of screening, immunohistochemical staining speciﬁc for CMV-pp65 was done on BHK-
21 cells infected with recombinant MVA containing the CMV-pp65 expression cassette
inserted into either the del II site or the IGR3 site. Uninfected BHK-21 cells were used as
a (-) staining control. (B) Growth kinetics of rMVA-pp65-IGR3 in BHK-21 and CEF cells.
BHK-21 or CEF cells (4×106/100 mmdish) were infected with 4×104 pfu (MOI=0.01)
of rMVA-pp65-IGR3. Cell lysates were generated 2, 24, 48, and 72 hours after infection
and used for viral titer by immunohistochemical staining. (C) Western blot analysis of
transgene expression from a rMVA-pp65-IGR3 isolate after puriﬁcation. Total cell
lysates were generated from BHK-21 cells infected with either puriﬁed rMVA-pp65-del
II or rMVA-pp65-IGR3 and 30 µg of total lysate were loaded for western blot analysis.
Details of the approaches can be found in Materials and Methods.
Fig. 3. Genetic stability during passage of recombinant MVA-pp65-IGR3. (A) Following
puriﬁcation of rMVA-pp65-IGR3, transgene stability was determined by quantitative
PCR (ABI 7300 Real-Time PCR System) during 10 passages on BHK-21 cells. Copy ratios
are expressed as transgene copies (CMV-pp65) to MVA backbone copies. The analysis
was repeated 3 times and shown is the mean of all 3 runs. Error bars represent standard
error of the mean (SEM). Details of the approach are described in Materials and
Methods. (B) Using primers speciﬁc for the IGR3 ﬂanking region (Table 1), PCR analysis
was performed using a Perkin Elmer 9600 Gene Amp PCR system to detect for the
presence or absence of wildtype (wt) IGR3 sequence (∼300 bp) and the CMV-pp65
expression cassette (∼2.7 kb) in viral genomic DNA isolated from rMVA-pp65-IGR3 at
passages 1, 5, and 10. (C) Western blot analysis of CMV-pp65 at passages 1, 5, and 10.
Equal amounts of total protein lysate (30 ug, Bradford assay) were loaded for each
sample. Additional western blot against vaccinia protein using an anti-BR8 vaccinia
mAb was performed as a loading control.
Table 1
Primers used in generation of IGR3 transfer vector and PCR analysis of virus stability
during passage.
Target Gene Primer Sequences
MVA IGR3 FL1 Forward: 5' CCGGAATTCCACCTTCTATAGATCTGAG 3'
Reverse: 5' GGTACCGCGCGTGTCGACTCAAATGAGATAAAGTG-
AAAATATATATC 3'
MVA IGR3 FL2 Forward: 5' CATTTGAGTCGACACGCGCGGTACCGAATAAAAAT-
GTTTTTGTTTAACCACTGCA 3'
Reverse: 5' CGCGAATTCGGAATTGGGAACCTCTAAAAG 3'
MVA IGR3 (qPCR) Forward: 5' AACACCCGCACAAGTCTG 3'
Reverse: 5' TCCGCTCCCATTCAATTC 3'
CMV pp65 (qPCR) Forward: 5' A TCAAACCGGGCAAGATCTCGC 3'
Reverse: 5' ATCGTACTGACG CAGTTCCACG 3'
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were predominantly ≥1 through 10 passages, indicating that the
CMV-pp65 transgene is likely retained in nearly 100% of viral isolates.
However, since the primers used in the qPCR assay target only part of
the CMV-pp65 transgene (Table 1) and can not detect mutations or
deletions that would likely affect transgene expression, it was
necessary to analyze the ratio of rMVA expressing CMV-pp65 to
total MVA virus. By employing immunohistochemistry staining of
BHK-21 cells infected with rMVA-pp65-IGR3 from passages 1, 5 and
10, and using CMV-pp65-speciﬁc mAb (for transgene expression) and
vaccinia-speciﬁc mAb (for total MVA virus)(Schmelz et al., 1994), we
found that greater than 97% of MVA expressed CMV-pp65 at each
passage (Table 2).
To ensure that nowildtypeMVA had been ampliﬁed during passage,
we conﬁrmed the presence of the entire CMV-pp65 expression cassette(∼2.7 kb) in rMVA-pp65-IGR3 and also the absence of wildtype MVA
(∼300 bp) at passages 1, 5, and 10 by PCR analysis (Fig. 3B) using
primers speciﬁc for the IGR3 region (Table 1). At the same time, we also
Table 2
CMV-pp65 expression by serially passaged rMVA-pp65-IGR3.
Passage % pp65 staining plaques out of total rMVA
1 100 (n=83)
5 98 (n=53)
10 100 (n=95)
n represents total number of anti-BR8 vaccinia staining plaques.
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analysis (Fig. 3C). Lastly, andmost importantly, sequencing of the CMV-
pp65 transgene from puriﬁed DNA of rMVA-pp65-IGR3 viral isolates
(n=6) revealed no variation in transgene sequence at passages 1 or 5,
and we found only a single nucleotide mutation that resulted in an
amino acid change fromArg to His at residue position 494 in 1 isolate at
passage 10 (Table 3). Altogether, these data further highlight the
capacity for IGR3 to serve as a stable site of recombinant transgene
insertion.Immunogenicity in HHDII transgenic mice
Although the genetic stability of various IGRs have been partially
assessed in previous work (Timm et al., 2006), immunogenicity of
genes inserted into these sites is not well known. We therefore
evaluated the immunogenicity of puriﬁed rMVA-pp65-IGR3 in the
transgenic HLA-A2 (HHDII) murinemodel system. HHDII mice (n=4)
were inoculated intraperitoneally with 5.0×107 pfu of puriﬁed rMVA-
pp65-IGR3. Spleens were harvested 3 weeks later and CD8+ spleno-
cytes were assessed for IFN-γ production by intracellular cytokine
staining (ICS) following ex vivo or 7 day in vitro stimulation (IVS) with
a known HLA-A2-restricted CMV-pp65 epitope (pp65495-503) (Dia-
mond et al., 1997; Wang et al., 2007; Wills et al., 1996). Following
7 day IVS of splenocytes with pp65495-503-loaded LCLs, we observed
dramatic increases in CMV-pp65-speciﬁc CD8+IFN-γ+ responses,
ranging from 70% to 79% (Fig. 4A, bottom left) of the total CD8+
response with mock responses ranging from 0.7% to 1.5% (Fig. 4A,
bottom right) of the total CD8+ response. Surprisingly, splenocytes
from rMVA-pp65-IGR3-vaccinated HHDII mice, stimulated ex-vivo
with pp65495-503 peptide, consistently generated CD8+IFN-γ+
responses ranging from 6.0% to as high as 9.8% (Fig. 4A, top left) of
the total CD8+ response, which were signiﬁcantly higher than mock
(irrelevant peptide) stimulated responses that measured between
0.10% to 1.7% of the total CD8+ response (Fig. 4A, top right and Fig. 4B).
Such ex-vivo responses are not always readily observed when
immunizing with rMVA containing transgenes, such as CMV-pp65,
inserted into del sites (Krishnan et al., 2008; Wang et al., 2007). We
therefore compared ex-vivo CD8+IFN-γ+ splenocyte responses of
HHDIImice immunizedwith rMVA containing CMV-pp65 in either del
II or IGR3 (Fig. 4C). We observed signiﬁcantly higher CMV-pp65-
speciﬁc responses in HHDII mice vaccinated with rMVA-pp65-IGR3
compared to those vaccinated with rMVA-pp65-del II (Pb0.03, Mann-
Whitney). The consistent transgene-speciﬁc immune responses
generated ex-vivo and after IVS by rMVA-pp65-IGR3 in the HHDII
murine system further highlight the potential usefulness of IGR3 as an
effective antigen gene insertion site.Table 3
Sequence analysis of CMV-pp65 gene in passaged rMVA - pp65- IGR3.
Passage Sequence Match to Input Virus
1 6 of 6 isolates, 100% match
5 6 of 6 isolates, 100% match
10 5 of 6 isolates, 100% match; 1 of 6 contained 1 a.a. change*
* an amino acid (a.a.) change of Arg to His occurred at a.a. position 494 in this isolate.Stable immunogenicity after 7 passages assessed in HHDII transgenic
mice
It is common to observe instability of transgene expression
following multiple passages of rMVA in culture, which can ultimately
result in decreased immunogenicity of puriﬁed vaccine stocks
(Burgers et al., 2008; Wyatt et al., 2009). Therefore, to determine
whether successive passage of rMVA-pp65-IGR3 changes its immu-
nogenic properties, we immunized HHDII mice (n=4) with virus that
had been passaged seven times in BHK-21 cells. IVS responses
generated by this immunization (Fig. 4D) were not signiﬁcantly
different from those seen in mice immunized with puriﬁed,
unpassaged rMVA-pp65-IGR3 (P=1.0, Mann-Whitney test), ranging
from 58% to 81% of the total CD8+ response with mock responses
ranging from 0.3% to 1.27% of the total CD8+ response. These data
demonstrate the continued ability of rMVA-pp65-IGR3 to sustain
robust immunogenicity following multiple passages in-vitro. Stable
levels of immunogenicity is a valuable property during extended
passage required to sustain the vaccine manufacturing process.
rMVA-pp65-IGR3 infection of human PBMC and expansion of a memory
T cell repertoire
Following these preliminary experiments in the HHDII murine
system, we next investigated the potential of rMVA-pp65-IGR3 to
elicit human T cell memory responses using PBMC. Autologous PBMC
were used as APC for IVS of PBMC from 2 healthy individuals after
conditioning for 2 days with a cocktail of CpG ODN as described in
Material andMethods. The heterogeneous population of APC becomes
more capable of being infected with puriﬁed rMVA-pp65-IGR3. As
shown in Fig. 5, CD8+IFN-γ+ responses to CMV-pp65 ranged from
23% to 36% of the total CD8+ T cell response with responses from
mock stimulation ranging from 0.02% to 0.05%. The signiﬁcantly
robust immune responses generated by rMVA-pp65-IGR3 in human
PBMC further emphasizes the potential of IGR3 as an alternate, or an
addition, to del sites for insertion of transgenes.
Discussion
Our results indicate that IGR3 deﬁnes a useful site of insertion in
MVA because it maintains genetic stability of a wide variety of inserts
including CMV-pp65, and allows for stable expression of proteins
from transgenes that result in robust transgene-speciﬁc immune
responses. Previous studies have assessed the stability of transgenes
in IGRs (Timm et al., 2006), but have only in a single instance
evaluated immunogenicity of genes in these insertion sites (Wyatt et
al., 2009). The study of an HIV glycoprotein showed that a sequence
and structural alteration of the membrane form of the glycoprotein
expressed as a recombinant transgene was necessary to achieve
stable expression during passage. For the ﬁrst time we show that a
transgene inserted into IGR3 of the MVA genome is able to
consistently generate CD8+IFN-γ+ responses in both a transgenic
HHDII murine model and in human PBMC. We also show that the
inserted transgene (CMV-pp65) and expression levels are nearly
100% retained following multiple passages in-vitro, which in part
may contribute to the enhanced magnitude and consistency of
immune responses after serial passages of the recombinant virus
during passage.
Transgene expression that results in adverse effects to MVA
replication is often minimized by mutation or genetic truncation, to
achieve optimal replication (Wyatt et al., 2009). Several consequences
of inappropriate changes in antigen sequence include potential loss of
diversity of MHC recognition, improper folding and processing of the
truncated protein which may lead to poor immunogenicity, or more
worrisome new regulatory properties generated by a change in
primary sequence. Based on observations made in this study, IGR3
Fig. 4. Immunogenicity of rMVA-pp65-IGR3 in HHDII transgenic mice. (A) HLA-A2 pp65-speciﬁc IFN-γ+ T cell responses generated by CD8+ splenocytes from transgenic HHDII mice
immunized with puriﬁed rMVA-pp65-IGR3. HHDII mice (n=4) were inoculated intraperitoneally (i.p.) with 5×107 pfu of rMVA-pp65-IGR3. Splenocytes were harvested 3 weeks
post-immunization and assessed for IFN-γ production ex-vivo and after in-vitro stimulation (IVS) to a known HLA-A2-restricted pp65 epitope (pp65495-503) by FACS analysis. Shown
is a representative mouse for the ex-vivo and IVS groups. Mock groups represent re-stimulation with irrelevant peptide. (B) pp65495-503-speciﬁc IFN-γ+ responses generated ex-vivo
by CD8+ splenocytes from HHDII mice (n=4) immunized i.p. with 5×107 pfu of puriﬁed rMVA-pp65-IGR3. Error bars represent SEM. Differences in pp65495-503-speciﬁc IFN-γ+
responses compared tomock stimulated responses were evaluated using the Mann-Whitney test and a P valueb0.05 is considered signiﬁcant. Details of the approaches can be found
in Materials and Methods. (C) pp65495-503-speciﬁc IFN-γ+ responses generated ex-vivo by CD8+ splenocytes from HHDII mice (n=4) immunized i.p. with 5×107 pfu of either
puriﬁed rMVA-pp65-IGR3 or rMVA-pp65-del II. Error bars represent SEM. Differences in responses were evaluated using the Mann-Whitney test and a P valueb0.05 is considered
signiﬁcant. (D) pp65495-503-speciﬁc IFN-γ+ responses generated through IVS by CD8+ splenocytes from HHDII mice (n=4) immunized i.p. with 5×107 pfu of puriﬁed rMVA-pp65-
IGR3 after 7 passages were compared to responses frommice immunized i.p. with 5×107 pfu unpassaged rMVA-pp65-IGR3. Error bars represent SEM. Differences in responses were
evaluated using the Mann-Whitney test and a P valueN0.05 is not considered signiﬁcant.
Fig. 5. Memory T-cell responses to CMV-pp65 after infection of human PBMC with
rMVA-pp65-IGR3. CD8+ pp65-speciﬁc IFN-γ+ responses were generated from human
PBMCs of 2 CMV-positive healthy subjects (HS1, HS2). The approach used in-vitro
stimulation with rMVA-pp65-IGR3-infected autologous PBMC, after conditioning using
a cocktail of CpG ODN. Details of the approaches can be found inMaterials andMethods.
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expression and immunogenicity of unmodiﬁed transgenes that prove
unstable or are shown to have poor immunogenicity in known del
sites(Wang et al., 2004a; Wyatt et al., 2008). Under suboptimal
treatment conditions that utilize only single antigens or epitopes in a
vaccine regimen, certain cancers or infectious diseases may only be
weakly controlled and have increased probability to evade immune
surveillance. Therefore, IGR3 may serve as an additional site of
insertion for multiple genes into MVA, where immunization against a
diversity of tumor or viral antigens is necessary for greatest
protection, such as is the case for HIV, CMV, and numerous cancers
(Earl et al., 2009; Fischer et al., 2007; Gomez et al., 2007; Maruyama et
al., 2000; Mooij et al., 2004; Wang et al., 2006, 2007; Young et al.,
2001). Dual use of IGRs that are located between conserved MVA
genes described in recent reports may serve as a more stable
alternative to the use of dual insertion in del sites (Wyatt et al.,
2009). Recently, we have continued to explore the usefulness of the
IGR3 site for incorporation of additional inserts that include human
and murine Survivin and murine p53. These additional gene products
have proven to be well expressed and the viruses that contain them
are stable throughout their puriﬁcation and subsequent passage (data
not shown). These preliminary results indicate that the prospects for
using IGR3 for a wide array of genes is likely, and further conﬁrms and
extends its potential as an insertion site for a wide variety of antigens
that can be incorporated into MVA vectors and explored as vaccines
for infectious disease and cancer.
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Cells, viruses, peptides, and mice
BHK-21 cells (ATCC CCL-10) were purchased from American Type
Culture Collection (Manassas, VA) and maintained in minimal
essential medium (MEM) supplemented with 10% fetal calf serum
(ISC BioExpress, Kaysville, UT) in a 37° incubator containing 5% CO2.
Chicken embryo ﬁbroblasts (CEF) were purchased from Charles River
Laboratories (Wilmington, MA) as a cell suspension that is freshly
prepared weekly by the company. Cells are counted and frozen when
they arrive, and are thawed and plated followed by 24 hour resting
phase prior to infection with viruses. Wildtype (wt) MVA virus stock
was kindly provided by Drs. Linda Wyatt and Bernard Moss
(Laboratory of Viral Diseases, NIAID, NIH). mH5-pp65 inserted into
deletion 2 (del II) of MVA is described in a recent publication from our
laboratory(Wang et al., 2008, 2010). Peptide epitopes used in the
mouse immunization studies and ﬂow cytometry were prepared in
our laboratory using standard Fmoc peptide synthesis techniques
(Wang et al., 2008). HHDII mice are transgenic for HLA-A2 and have
knockout of mouse MHC Class I and β2-microglobulin loci and have
been used previously for evaluation of other rMVA expressing CMV
genes in our laboratory (Krishnan et al., 2008; Pascolo et al., 1997).
Construction of MVA transfer plasmid and viruses containing IGR3
sequences
The ﬁrst step in the process of generating a transfer plasmid
incorporating the IGR3 segment of the MVA genome required
ampliﬁcation of the IGR3 genome from wildtype MVA genomic
DNA. Primers were made to subdivide the IGR3 region into two
segments that are ﬂanked with Eco R1 and contain Sal1/Acc65I
restriction enzyme sites. The sequence of the two pairs of primers are
shown in Table 1. Conditions for PCR ampliﬁcation from the MVA
genome were 95 °C for 5 min, 30 cycles of 95 °C for 1 min, 55 °C for
1 min, 72 °C for 3 min, and ending with a ﬁnal cycle at 72 °C for
10 min. The modiﬁed fragment that contains Sal1/Acc65I sites and
ﬂanked by terminal EcoR1 sites was cloned into the plasmid transfer
vector pCR 2.1 (Invitrogen) and referred to as pCR 2.1-IGR3. The IGR3
segment was further modiﬁed by insertion of an expression cassette
that was previously described and contains a multiple cloning site
(MCS) followed by a synthetically generatedmH5 promoter sequence
and a p7.5 promoter that drives the Venus™ (Clontech) ﬂuorescent
marker gene which was inserted into the transfer vector(Wang et al.,
2010). The completed transfer vector is shown in Fig. 1C and was
further modiﬁed by cloning the CMV-pp65 gene into the MCS to
complete the insertion vector for MVA. All plasmid vectors were
sequenced on both strands using an ABI 3730 located in the DNA
sequencing/Solexa Core facility of Beckman Research Institute of City
of Hope (COH). rMVA-pp65-IGR3 was generated by transfecting the
CMV-pp65 transfer vector into wt MVA-infected BHK-21 cells and
screened based on the Venus™ ﬂuorescent marker to eliminate wt
MVA according to our published procedures (Wang et al., 2008). Cell
debris were puriﬁed from ﬁnal stocks of rMVA-pp65-IGR3 through
ultracentrifugation on a sucrose gradient at 16,000 rpm for 80 min
using a Sorvall Discovery 90 (SA-600 rotor). Viral pellets were then
washed, ultracentrifuged for 60 min, and resuspended in aqueous
7.5% lactose/10 mM Tris (pH 7.5) and frozen at -80 °C for long term
storage.
Immunohistrochemical staining of rMVA-pp65-IGR3 in BHK-21 and CEF
cells
For growth kinetic studies, BHK-21 and CEF monolayers were
grown to a density of 4×106 cells/100 mm dish and then infected
with rMVA-pp65-IGR3 at an MOI of 0.01 (4×104 pfu/ml startinginput). Infected 100 mmdishes were then harvested at 2 h, 24 h, 48 h,
and 72 h after initial infection and resuspended in 1.0 ml of MEM
containing 2% fetal calf serum (MEM-2) and subjected to 3x freeze/
thaw cycles followed by sonication to release the virus. Virus from
each time point was subsequently titrated by immunostaining of
virus-infected cell foci on BHK-21 monolayers using polyclonal
vaccinia virus-speciﬁc antibody (Biogenesis Ltd., Poole, England, Cat.
No. 9503-2057), reconstituted in saline buffer (120 mM NaCl, 10 mM
TrisCL, pH 7.4) and used at a dilution of 1:2000. For genetic stability
studies, BHK-21 monolayers were infected with a dilution (10-7) of
puriﬁed, passaged rMVA-pp65-IGR3 (passages 1, 5, or 10). Immuno-
histochemistry staining was then performed as described above using
puriﬁed mAb 28-103 (Wang et al., 2004b) against CMV-pp65 or anti-
BR8-speciﬁc vaccinia mAb (Schmelz et al., 1994). The percentage of
CMV-pp65-containing rMVA is calculated as: (CMV-pp65 staining
plaques/BR8-speciﬁc vaccinia staining plaques)×100%.
Western blot detection of rMVA protein expression
Protein expression levels by the CMV-pp65 transgene were
measured by WB using the Amersham ECL Plus™ detection kit
(Amersham Pharmacia Biotech, Buckinghamshire, United Kingdom).
Cell lysates were separated by 10% SDS-PAGE. After electrotransfer of
proteins from the gel onto PVDF membranes (Bio-Rad, Hercules, CA),
the blots were incubated with puriﬁed mAb 28-103 (Wang et al.,
2004b) against CMV-pp65, or anti-BR8-speciﬁc vaccinia antibody
used for a loading control (Schmelz et al., 1994), then washed and
further incubated with HRP-labeled goat anti-mouse polyclonal
antibody according to the manufacturer instructions (Amersham
Pharmacia Biotech, Buckinghamshire, United Kingdom). These meth-
ods closely follow our recent publications (Wang et al., 2008, 2010).
qPCR and sequencing analysis of rMVA-pp65-IGR3
rMVA-pp65-IGR3 viruses were serially passaged 10 times on BHK-
21 cells. Brieﬂy, BHK-21 cells growing on 150 mm tissue culture
dishes were infected with rMVA at MOI=0.1. rMVA viruses were
harvested 48 hours after infection, resuspended in 1.0 ml of MEM
containing 2% fetal calf serum (MEM-2) and subjected to 3x freeze/
thaw cycles followed by sonication to release the virus. The virus from
each passage was subsequently titrated on BHK-21 cells, and after
adjustment to an MOI of 0.10, it was used for the next passage on
BHK-21 cells. Viral DNA from each passage was puriﬁed for qPCR
analysis using the Qiagen™ (Valencia, CA) column puriﬁcation kit
according to the manufacturers instructions. Cell lysates of each
passage used for qPCR analysis were prepared from 100 mm dishes of
BHK-21 cells infected with the same amount of rMVA viruses from
each serial passage. The plasmid DNA used to generate the standard
curve was made by inserting the pp65 gene into the pSC11 vector
containing the TK gene (Wang et al., 2010). The absolute concentra-
tion of the plasmid was measured by two independent means: OD260
by UV spectraphotometry and the ﬂuorophor based method using
Quant-iT™ Picogreen© DS DNA kit (Invitrogen, Carlsbad, CA). The
concentration was converted to plasmid copy number using the
molecular weight of the plasmid DNA. The primers to measure pp65
and MVA backbone copies were designed based on standard qPCR
conditions using primer express software version 3.0 (Applied
Biosystems Inc., Foster City, CA) and listed in Table 1. Primers for
detection of CMV-pp65 using qPCR generate a ∼190 bp fragment
derived from the 1.70 kb gene. qPCRwas performed using an ABI 7300
real time PCR system and Power SYBR Green Master Mix Kit (ABI).
Brieﬂy, 5 μL of MVA genomic DNA was ampliﬁed in a mixture of 25 μL
containing 1 μM forward, 1 μM reverse primers and SYBR Green
containing solution. The thermocycling conditions were 95 °C for
10 min and 40 cycles at 95 °C for 15 s and 60 °C for 1 min. Gene copy
numbers were calculated using ABI sequence detection software
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gene copy number/MVA backbone copy number) was calculated for
each passage. The copy numbers for each gene was normalized to 1.0
for passage 1 and subsequent passages were computed based upon
the measured level at passage 1.
For PCR and sequencing analysis, rMVA-pp65-IGR3 genomic DNA
isolated from infected BHK-21 cells at passages 1, 5, and 10 were
subjected to PCR using IGR3 FL1 forward and IGR3 FL2 reverse primers
shown in Table 1. A Perkin Elmer 9600 Gene Amp PCR system was
used in conjunction with GoTaq GreenMaster Mix (Promega, San Luis
Obispo, CA) for all PCR reactions. Fragments were then either run on a
1% agaraose ethidum bromide gel or cloned into pCR2.1 (Invitrogen)
for sequencing using an ABI 3730 located in the DNA sequencing/
Solexa Core facility of Beckman Research Institute of City of Hope
(COH).
Immunogenicity of rMVA-pp65-IGR3 in HHDII transgenic mice
HHDII mice (transgenic HLA A2.1) were used at 10-12 weeks for
immunization and were bred and maintained under SPF conditions
(microisolator cages with top ﬁltration and automatic water feed lines
contained within a multi-rack suite) in the COH centralized animal
core facility. HHDII mice were immunized with 5×107 pfu of puriﬁed
rMVA by the intraperitoneal (i.p.) route. After 3 weeks post-
immunization, spleens were removed and were stimulated in-vitro
for 1 week using a simpliﬁed protocol with HLA-matched EBV-LCL
(Krishnan et al., 2008) as antigen presenting cells (APC) loaded either
with the relevant CMV-CTL epitope HLA-A*0201 pp65495-503 (pp65-
A2) (Diamond et al., 1997) or an irrelevant HLA A*0201-speciﬁc
epitope from HIV-gag (Johnson et al., 1991). For some experiments
shown in Fig. 4A, no IVS was used, and fresh splenocytes were
harvested immediately after euthanasia and processed for ICC
(intracellular cytokine) assays as described below. ICC was used to
measure pp65 IFN-γ+/CD8+ T cells from the stimulated splenocytes
according to previously describedmethods (Krishnan et al., 2008). 0.5
to 1.0×106 events were acquired for each sample on a FACSCanto™
ﬂow analyzer (BD Biosciences, San Jose, CA). Analysis was performed
using FCS Express version 2 software (De Novo, Ontario, Canada). The
number of double positive cells is expressed as a percentage of the
CD8+ T cell population.
Immunogenicity of rMVA-pp65-IGR3 in human PBMC
In-vitro stimulation using rMVA-pp65-IGR3 was modiﬁed from a
publishedmethod (La Rosa et al., 2006). Brieﬂy, cryopreserved PBMCs
were rapidly thawed and immediately dispensed in a 12-well plate at
a concentration of 2×106 cells/mL in RPMI 1640 medium (2.5 mL/
well) supplemented with 10% human AB serum (COH Blood Bank)
and were incubated with 5 μg/mL of both CpG-A ODN 2216 and CpG-
B ODN 2006 (TriLink BioTechnologies, San Diego, CA, USA). After
3 days, ODN-treated PBMCs were infected with rMVA-pp65-IGR3 at a
multiplicity of infection of 5, for 6 hours in RPMI 1640 medium with
reduced (2%) human AB serum. Infected PBMCs were γ-irradiated
(2500 rads) and used as APC. APC were plated in a 24-well plate
(1.5×106/well), co-incubated with autologus PBMC (3×106/well), in
a ﬁnal volume consisting of 2 ml/well RPMI 1640 medium with 10%
human AB serum and human rIL-2 (NIH AIDS Research and Reference
Reagent Program, 10 units/ml). Every 2 days, 50% of the culture
medium was removed, and replaced with fresh medium containing
rIL2. Cells were incubated for 8 days and split into additional wells
when necessary. At day 8, cells were collected and washed with
mediumwithout rIL-2 and transferred into 15 ml Falcon tubes in 1 mL
medium without rIL-2 and starved overnight. PBMC were then
incubated with a pp65 Pepmix™ of overlapping 15 mers (JPT, Berlin,
Germany) or peptide library diluent for 1.5 hrs and then GolgiPlug
containing brefeldin A (BD Biosciences) was added. After 12 hours ofincubation, PBMC were harvested, washed, labeled with PE–conju-
gated anti-CD8 antibody, ﬁxed, and permeabilized (Cytoﬁx-Cyto-
perm; Becton Dickinson Biosciences) before they were labeled with
APC–conjugated antibody to IFN-γ. The stained cells were analyzed on
a FACSCanto™ (BD Immunocytometry Systems, San Jose, CA), and
data were analyzed using FCS Express (version 3.0; DeNovo
Software). 0.5×106 events were acquired for each sample. Lympho-
cytes were initially gated using forward vs side scatter, and then CD8+
lymphocytes were gated separately. The number of IFN-γ expressing
cells in the upper right quadrant is shown as a percentage of the CD8+
lymphocyte population.
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